Cutaneous adverse events associated with vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma: an observational study of 30 treated patients and presentation of a management algorithm

被引：0
作者：
Sinha, R. [1 ]
Edmonds, K. [2 ]
Newton-Bishop, J. A. [3 ]
Gore, M. [2 ]
Larkin, J. [2 ]
Fearfield, L. A. [1 ]
机构：
[1] Chelsea & Westminster Hosp, London, England
[2] Royal Marsden Hosp, London SW3 6JJ, England
[3] Univ Leeds, Leeds, W Yorkshire, England
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2012年 / 167卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：9 / 10
页数：2
相关论文
共 50 条
  • [31] Pilot study of vemurafenib and panitumumab combination therapy in patients with BRAF V600E mutated metastatic colorectal cancer.
    Yaeger, Rona D.
    Cercek, Andrea
    O'Reilly, Eileen Mary
    Reidy, Diane Lauren
    Kemeny, Nancy E.
    Wolinsky, Tamar
    Gollub, Marc J.
    Lacouture, Mario E.
    Rosen, Neal
    Vakiani, Efsevia
    Saltz, Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [32] Vemurafenib (V) in BRAF V600E metastatic melanoma (mM): Analysis of 507 patients (pts) enrolled in the French temporary authorization for use (ATU)
    Lebbe, Celeste
    Robert, Caroline
    Dreno, Brigitte
    Thomas, Luc
    Grob, Jean Jacques
    Meyer, Nicolas
    Regnier-Rosencher, Elodie
    Saiag, Philippe
    Mortier, Laurent
    Hospital, Valerie
    Duval-Modeste, Anne Benedicte
    Dalac-Rat, Sophie
    Lesimple, Thierry
    Guillot, Bernard
    Leccia, Marie Therese
    Bitoun, Laurence
    Bobadilla, Luz
    Jouary, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] Three Lung Squamous Cell Carcinomas Patients Positive for BRAF V600E Mutation
    Hashimoto, N.
    Moriya, R.
    Kako, H.
    Akao, K.
    Souma, T.
    Oya, Y.
    Goto, Y.
    Isogai, S.
    Kondo, M.
    Imaizumi, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [34] Cerebrospinal fluid concentrations of vemurafenib in patients treated for brain metastatic BRAF-V600 mutated melanoma
    Sakji-Dupre, Lilia
    Le Rhun, Emilie
    Templier, Carole
    Desmedt, Eve
    Blanchet, Benoit
    Mortier, Laurent
    MELANOMA RESEARCH, 2015, 25 (04) : 302 - 305
  • [35] Retrospective, correlative study of BRAF mutation V600E in testicular cancer patients
    Satpute, Shailesh R.
    Koster, Roelof
    Nathanson, Katherine L.
    Vaughn, David J.
    Albany, Costantine
    Einhorn, Lawrence H.
    Hanna, Nasser H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] Immunohistochemistry as a quick screening method for clinical detection of BRAF(V600E) mutation in melanoma patients
    Chen, Qiongrong
    Xia, Chunjiao
    Deng, Yunte
    Wang, Mingwei
    Luo, Ping
    Wu, Changming
    Yue, Junqiu
    Fang, Na
    Wang, Manxiang
    Wei, Shaozhong
    TUMOR BIOLOGY, 2014, 35 (06) : 5727 - 5733
  • [37] Detection of BRAF V600E mutation by droplet digital PCR in plasma of patients with malignant melanoma
    Burjanivova, T.
    Malicherova, B.
    Grendar, M.
    Minarikova, E.
    Bobrovska, M.
    Vanova, B.
    Kasubova, I.
    Jezkova, E.
    Homola, I.
    Pecova, T.
    Lasabova, Z.
    Plank, L.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 437 - 437
  • [38] Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma
    Menzies, Alexander M.
    Haydu, Lauren E.
    Visintin, Lydia
    Carlino, Matteo S.
    Howle, Julie R.
    Thompson, John F.
    Kefford, Richard F.
    Scolyer, Richard A.
    Long, Georgina V.
    CLINICAL CANCER RESEARCH, 2012, 18 (12) : 3242 - 3249
  • [39] Cell-free DNA V600E measurements during vemurafenib therapy of metastatic melanoma patients
    Kozak, K.
    Lugowska, I.
    Kowalik, A.
    Gos, A.
    Jurkowska, M.
    Stepniak, J.
    Switaj, T.
    Paterczyk, H. Kosela
    Klimczak, A.
    Falkowski, S.
    Jagielska, B.
    Siedlecki, J.
    Chlopek, M.
    Kalisz, J.
    Rutkowski, P.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S684 - S684
  • [40] Safety and Efficacy of Vemurafenib in Patients with BRAFV600 Mutation-Positive Metastatic Melanoma Previously Treated with Ipilimumab: a Subgroup Analysis from a Vemurafenib Expanded Access Program
    Hamid, O.
    Flaherty, L.
    Day, B. -M
    Abhyankar, S.
    Hainsworth, J.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2013, 11 : 54 - 55
12345